FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200567351> ?p ?o ?g. }

• W4200567351 endingPage "6088" @default.
• W4200567351 startingPage "6088" @default.
• W4200567351 abstract "Despite recent advances in the multimodal treatment of pancreatic ductal adenocarcinoma (PDAC), overall survival remains poor with a 5-year cumulative survival of approximately 10%. Neoadjuvant (chemo- and/or radio-) therapy is increasingly incorporated in treatment strategies for patients with (borderline) resectable and locally advanced disease. Neoadjuvant therapy aims to improve radical resection rates by reducing tumor mass and (partial) encasement of important vascular structures, as well as eradicating occult micrometastases. Results from recent multicenter clinical trials evaluating this approach demonstrate prolonged survival and increased complete surgical resection rates (R0). Currently, tumor response to neoadjuvant therapy is monitored using computed tomography (CT) following the RECIST 1.1 criteria. Accurate assessment of neoadjuvant treatment response and tumor resectability is considered a major challenge, as current conventional imaging modalities provide limited accuracy and specificity for discrimination between necrosis, fibrosis, and remaining vital tumor tissue. As a consequence, resections with tumor-positive margins and subsequent early locoregional tumor recurrences are observed in a substantial number of patients following surgical resection with curative intent. Of these patients, up to 80% are diagnosed with recurrent disease after a median disease-free interval of merely 8 months. These numbers underline the urgent need to improve imaging modalities for more accurate assessment of therapy response and subsequent re-staging of disease, thereby aiming to optimize individual patient's treatment strategy. In cases of curative intent resection, additional intra-operative real-time guidance could aid surgeons during complex procedures and potentially reduce the rate of incomplete resections and early (locoregional) tumor recurrences. In recent years intraoperative imaging in cancer has made a shift towards tumor-specific molecular targeting. Several important molecular targets have been identified that show overexpression in PDAC, for example: CA19.9, CEA, EGFR, VEGFR/VEGF-A, uPA/uPAR, and various integrins. Tumor-targeted PET/CT combined with intraoperative fluorescence imaging, could provide valuable information for tumor detection and staging, therapy response evaluation with re-staging of disease and intraoperative guidance during surgical resection of PDAC.A literature search in the PubMed database and (inter)national trial registers was conducted, focusing on studies published over the last 15 years. Data and information of eligible articles regarding PET/CT as well as fluorescence imaging in PDAC were reviewed. Areas covered: This review covers the current strategies, obstacles, challenges, and developments in targeted tumor imaging, focusing on the feasibility and value of PET/CT and fluorescence imaging for integration in the work-up and treatment of PDAC. An overview is given of identified targets and their characteristics, as well as the available literature of conducted and ongoing clinical and preclinical trials evaluating PDAC-targeted nuclear and fluorescent tracers." @default.
• W4200567351 created "2021-12-31" @default.
• W4200567351 creator A5002334736 @default.
• W4200567351 creator A5003445744 @default.
• W4200567351 creator A5007783184 @default.
• W4200567351 creator A5008414293 @default.
• W4200567351 creator A5018555118 @default.
• W4200567351 creator A5020233877 @default.
• W4200567351 creator A5024409239 @default.
• W4200567351 creator A5028075025 @default.
• W4200567351 creator A5044353837 @default.
• W4200567351 creator A5052450582 @default.
• W4200567351 creator A5052876669 @default.
• W4200567351 creator A5054231020 @default.
• W4200567351 creator A5058922925 @default.
• W4200567351 creator A5082190982 @default.
• W4200567351 creator A5083164288 @default.
• W4200567351 creator A5086101467 @default.
• W4200567351 date "2021-12-02" @default.
• W4200567351 modified "2023-10-16" @default.
• W4200567351 title "Overview and Future Perspectives on Tumor-Targeted Positron Emission Tomography and Fluorescence Imaging of Pancreatic Cancer in the Era of Neoadjuvant Therapy" @default.
• W4200567351 cites W1523096697 @default.
• W4200567351 cites W1963704146 @default.
• W4200567351 cites W1969709442 @default.
• W4200567351 cites W1975375759 @default.
• W4200567351 cites W1982925123 @default.
• W4200567351 cites W1983658560 @default.
• W4200567351 cites W1985720035 @default.
• W4200567351 cites W1987442612 @default.
• W4200567351 cites W1990948088 @default.
• W4200567351 cites W1991354544 @default.
• W4200567351 cites W1991732553 @default.
• W4200567351 cites W1994861753 @default.
• W4200567351 cites W1997664212 @default.
• W4200567351 cites W2000157190 @default.
• W4200567351 cites W2000844719 @default.
• W4200567351 cites W2002728088 @default.
• W4200567351 cites W2009512225 @default.
• W4200567351 cites W2011989463 @default.
• W4200567351 cites W2012005360 @default.
• W4200567351 cites W2018586721 @default.
• W4200567351 cites W2022797070 @default.
• W4200567351 cites W2023949193 @default.
• W4200567351 cites W2024263101 @default.
• W4200567351 cites W2024548886 @default.
• W4200567351 cites W2025342781 @default.
• W4200567351 cites W2026762108 @default.
• W4200567351 cites W2028588685 @default.
• W4200567351 cites W2029714432 @default.
• W4200567351 cites W2029851814 @default.
• W4200567351 cites W2030541057 @default.
• W4200567351 cites W2033520317 @default.
• W4200567351 cites W2035138526 @default.
• W4200567351 cites W2037550879 @default.
• W4200567351 cites W2038502210 @default.
• W4200567351 cites W2040319600 @default.
• W4200567351 cites W2040775084 @default.
• W4200567351 cites W2041521061 @default.
• W4200567351 cites W2045277166 @default.
• W4200567351 cites W2054158442 @default.
• W4200567351 cites W2059695788 @default.
• W4200567351 cites W2059717684 @default.
• W4200567351 cites W2060898028 @default.
• W4200567351 cites W2070128714 @default.
• W4200567351 cites W2074146371 @default.
• W4200567351 cites W2074899704 @default.
• W4200567351 cites W2076614074 @default.
• W4200567351 cites W2086756946 @default.
• W4200567351 cites W2090879385 @default.
• W4200567351 cites W2091811255 @default.
• W4200567351 cites W2091982207 @default.
• W4200567351 cites W2093507045 @default.
• W4200567351 cites W2095520368 @default.
• W4200567351 cites W2100709184 @default.
• W4200567351 cites W2103524840 @default.
• W4200567351 cites W2107780185 @default.
• W4200567351 cites W2108428882 @default.
• W4200567351 cites W2111805273 @default.
• W4200567351 cites W2117102341 @default.
• W4200567351 cites W2119810396 @default.
• W4200567351 cites W2124114323 @default.
• W4200567351 cites W2125932935 @default.
• W4200567351 cites W2126897065 @default.
• W4200567351 cites W2131392163 @default.
• W4200567351 cites W2134786525 @default.
• W4200567351 cites W2141067132 @default.
• W4200567351 cites W2142282255 @default.
• W4200567351 cites W2142514824 @default.
• W4200567351 cites W2145063333 @default.
• W4200567351 cites W2150293198 @default.
• W4200567351 cites W2150465988 @default.
• W4200567351 cites W2152183134 @default.
• W4200567351 cites W2155828430 @default.
• W4200567351 cites W2157048271 @default.
• W4200567351 cites W2159407099 @default.
• W4200567351 cites W2166573361 @default.
• W4200567351 cites W2167157100 @default.
• W4200567351 cites W2168845722 @default.

• next